Mar 14, 2024
I-Mab Reports Full Year 2023 Financial Results and Business Update
Feb 07, 2024
I-Mab Signs Agreement to Divest its Assets and Business Operations in China
Feb 25, 2021
I-Mab Announces First Patient Dosed in China Phase 3 Study of Eftansomatropin Alfa in Pediatric Patients with Growth Hormone Deficiency
Feb 24, 2021
I-Mab Announces Upcoming Participation at March Conferences
Feb 10, 2021
I-Mab Announces China NMPA Clearance for Phase 1 Study of TJ210/MOR210 in Patients with Advanced Solid Tumors
Feb 09, 2021
Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab Has Priced
Feb 05, 2021
Proposed Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab
Feb 05, 2021
I-Mab Announces Multiple Clinical Advancements of Its Differentiated CD73 Antibody Uliledlimab in China and the U.S.
Feb 04, 2021
I-Mab Announces First Patient Dosed in Phase 2 Clinical Trial of TJ107 in Glioblastoma Multiforme in China
Jan 25, 2021
I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer
Dec 23, 2020
I-Mab Announces Upcoming Participation at January Conferences
Dec 14, 2020
I-Mab Added to Nasdaq Biotechnology Index
Dec 01, 2020
I-Mab Files Shelf Registration Statement for PIPE Investors
Dec 01, 2020
I-Mab Appoints Leading Immunology and Hematology Experts to Its Scientific Advisory Board
Nov 11, 2020
I-Mab Announces Preclinical Data on Differentiated Anti-C5aR Antibody TJ210/MOR210 at SITC 2020
Nov 09, 2020
I-Mab Reports Phase 1 Clinical Trial Data of Highly Differentiated Anti-CD47 Monoclonal Antibody Lemzoparlimab at the 2020 SITC Annual Meeting
Oct 28, 2020
I-Mab Announces Upcoming Participation at November Conferences
Oct 27, 2020
I-Mab to Present Preclinical Data of TJ210 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Oct 15, 2020
I-Mab to Present Phase 1 Data of Lemzoparlimab at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Sep 30, 2020
I-Mab Receives China CDE Approval to Initiate Phase 3 Clinical Trial of Eftansomatropin in Pediatric Patients with Growth Hormone Deficiency